63
18. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor:
the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating
tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J
Neuroradiol 2000;21:901-9.
19. Tomoi M, Maeda M, Yoshida M, et al. Assessment of radiotherapeutic effect on
brain tumors by dynamic susceptibility contrast MR imaging: a preliminary report.
Radiat Med 1999;17:195-9.
20. Wenz F, Rempp K, Hess T, et al. Effect of radiation on blood volume in low-
grade astrocytomas and normal brain tissue: quantification with dynamic
susceptibility contrast MR imaging. AJR Am J Roentgenol 1996;166:187-93.
21. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas:
comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.
22. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of
permeability in high-grade and low-grade brain tumors using dynamic
susceptibility contrast MR imaging. AJR Am J Roentgenol 2002;178:711-6.
23. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined
cerebral blood volume maps with histologic and angiographic determination of
vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479-86.
24. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted
MR imaging of recurrent malignant gliomas treated with thalidomide and
carboplatin. AJNR Am J Neuroradiol 2000;21:881-90.
25. Lam WW, Chan KW, Wong WL, Poon WS, Metreweli C. Pre-operative grading of
intracranial glioma. Acta Radiol 2001;42:548-54.
26. Kleihues P, Cayenee W. World Health Organization Classification of Tumours:
Pathology and Genetics: Tumours of the Nervous System. 2nd edition ed. Lyon:
IARC Press - International Agency for Research on Cancer, 2000.
27. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas.
A simple and reproducible method. Cancer 1988;62:2152-65.
28. McCarthy BJ, Kruchko C. Consensus conference on cancer registration of brain
and central nervous system tumors. Neuro-oncol 2005;7:196-201.
29. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J
Clin 1999;49:8-31, 1.
30. Walker A, Robins M, Weinfeld F. Epidemiology of brain tumors: the national
survey of intracranial neoplasms. Neurology 1985;35:219-226.
31. Davis FG, Preston-Martin S. Epidemiology. Incidence and survival. In: Bigner
DD, McLendon RE, Bruner JM, eds. Russel and Rubinstein's Pathology of
Tumors of the Nervous System. 6 ed. London: Arnold, 1998:5-45.
32. Lantos PL, VanderBerg SR, Kleihues K. Tumours of the Nervous System. In:
Graham DI, Lantos PL, eds. Greenfield's Neuropathology. London: Arnold,
1996:583-879.
33. Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A.
Supratentorial grade II astrocytoma: biological features and clinical course.
Lancet Neurol 2003;2:395-403.
34. Holland BA, Kucharcyzk W, Brant-Zawadzki M, Norman D, Haas DK, Harper PS.
MR imaging of calcified intracranial lesions. Radiology 1985;157:353-6.
35. Daumas-Duport C, Monsaigneon V, Blond S, et al. Serial stereotactic biopsies
and CT scan in gliomas: correlative study in 100 astrocytomas, oligo-
astrocytomas and oligodendrocytomas. J Neurooncol 1987;4:317-28.
36. Grafin von Einsiedel H, Loffler W. Nuclear magnetic resonance imaging of brain
tumors unrevealed by CT. Eur J Radiol 1982;2:226-34.